|
|
News Breaks
|
November 19, 2009
|
| 08:01 EDT |  | ISIS |
| theflyonthewall.com: | Altair Therapeutics commences Phase IIa AIR645 study | | Altair Therapeutics announced the commencement of its IL-4 receptor alpha inhibitor bronchoprovocation trial. Study AIR645-CS2 is a phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of inhaled AIR645 in suppressing the asthmatic response in subjects with mild asthma. Results are expected in the third quarter of 2010. AIR645 was discovered by Isis Pharmaceuticals (ISIS) and licensed to Altair Therapeutics. :theflyonthewall.com |
|
|
News For ISIS From The Last 14 Days Check below for free stories on ISIS the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
